View ValuationEMS-CHEMIE HOLDING 将来の成長Future 基準チェック /26EMS-CHEMIE HOLDING利益と収益がそれぞれ年間6%と3.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に27.6% 5.6%なると予測されています。主要情報6.0%収益成長率5.55%EPS成長率Chemicals 収益成長10.7%収益成長率3.2%将来の株主資本利益率27.59%アナリストカバレッジGood最終更新日23 Jul 2026今後の成長に関する最新情報Price Target Changed • Jul 14Price target increased by 7.1% to CHF708Up from CHF661, the current price target is an average from 7 analysts. New target price is 7.1% below last closing price of CHF763. Stock is up 21% over the past year. The company is forecast to post earnings per share of CHF21.45 for next year compared to CHF19.95 last year.Price Target Changed • Jul 16Price target increased by 8.2% to CHF731Up from CHF675, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of CHF708. Stock is up 2.6% over the past year. The company is forecast to post earnings per share of CHF20.29 for next year compared to CHF19.56 last year.Price Target Changed • Oct 31Price target decreased to CHF757Down from CHF849, the current price target is an average from 7 analysts. New target price is 20% above last closing price of CHF630. Stock is down 31% over the past year. The company is forecast to post earnings per share of CHF23.96 for next year compared to CHF23.53 last year.Price Target Changed • Oct 26Price target decreased to CHF826Down from CHF902, the current price target is an average from 7 analysts. New target price is 24% above last closing price of CHF665. Stock is down 29% over the past year. The company is forecast to post earnings per share of CHF24.02 for next year compared to CHF23.53 last year.Price Target Changed • Jul 26Price target increased to CHF936Up from CHF844, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF966. Stock is up 21% over the past year.Price Target Changed • Apr 24Price target increased to CHF801Up from CHF712, the current price target is an average from 5 analysts. New target price is 9.3% below last closing price of CHF883. Stock is up 39% over the past year.すべての更新を表示Recent updates分析記事 • Aug 04Is EMS-CHEMIE HOLDING AG (VTX:EMSN) Potentially Undervalued?Let's talk about the popular EMS-CHEMIE HOLDING AG ( VTX:EMSN ). The company's shares received a lot of attention from...Buy Or Sell Opportunity • Jul 29Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to CHF809. The fair value is estimated to be CHF667, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 3.2% per annum. Earnings are also forecast to grow by 6.0% per annum over the same time period.Price Target Changed • Jul 14Price target increased by 7.1% to CHF708Up from CHF661, the current price target is an average from 7 analysts. New target price is 7.1% below last closing price of CHF763. Stock is up 21% over the past year. The company is forecast to post earnings per share of CHF21.45 for next year compared to CHF19.95 last year.お知らせ • Jul 13EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time.Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026分析記事 • Jan 14Estimating The Fair Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)Key Insights Using the 2 Stage Free Cash Flow to Equity, EMS-CHEMIE HOLDING fair value estimate is CHF601 EMS-CHEMIE...お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026分析記事 • Dec 27EMS-CHEMIE HOLDING AG's (VTX:EMSN) Share Price Could Signal Some RiskEMS-CHEMIE HOLDING AG's ( VTX:EMSN ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right...分析記事 • Nov 12Investors Met With Slowing Returns on Capital At EMS-CHEMIE HOLDING (VTX:EMSN)If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...分析記事 • Oct 27Is EMS-CHEMIE HOLDING (VTX:EMSN) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Sep 01First half 2025 earnings released: EPS: CHF10.71 (vs CHF10.66 in 1H 2024)First half 2025 results: EPS: CHF10.71 (up from CHF10.66 in 1H 2024). Revenue: CHF1.02b (down 6.2% from 1H 2024). Net income: CHF250.4m (flat on 1H 2024). Profit margin: 25% (up from 23% in 1H 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 3% per year.Upcoming Dividend • Aug 05Upcoming dividend of CHF17.25 per shareEligible shareholders must have bought the stock before 12 August 2025. Payment date: 14 August 2025. Payout ratio is a comfortable 71% and the cash payout ratio is 90%. Trailing yield: 2.7%. Lower than top quartile of Swiss dividend payers (3.9%). In line with average of industry peers (2.8%).お知らせ • Jul 15EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time.Declared Dividend • Jul 14Dividend increased to CHF17.25Dividend of CHF17.25 is 7.8% higher than last year. Ex-date: 12th August 2025 Payment date: 14th August 2025 Dividend yield will be 2.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (71% earnings payout ratio) but not adequately covered by cash flows (90.1% cash payout ratio). The dividend has increased by an average of 3.7% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jul 13EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.お知らせ • Apr 01EMS-CHEMIE HOLDING AG to Report Fiscal Year 2024 Final Results on Jul 11, 2025EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2024 final results on Jul 11, 2025Reported Earnings • Mar 31Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: CHF19.70 (up from CHF19.56 in FY 2023). Revenue: CHF2.09b (down 5.5% from FY 2023). Net income: CHF460.8m (flat on FY 2023). Profit margin: 22% (up from 21% in FY 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 12% per year.Buy Or Sell Opportunity • Mar 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 7.2% to CHF677. The fair value is estimated to be CHF561, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 4.9% over the last 3 years. Earnings per share has declined by 7.8%. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings are also forecast to grow by 5.0% per annum over the same time period.お知らせ • Nov 27EMS-CHEMIE HOLDING AG to Report Fiscal Year 2024 Results on Feb 07, 2025EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2024 results on Feb 07, 2025お知らせ • Oct 23EMS-CHEMIE HOLDING AG to Report First Half, 2025 Results on Jul 11, 2025EMS-CHEMIE HOLDING AG announced that they will report first half, 2025 results on Jul 11, 2025Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 02First half 2024 earnings: EPS and revenues miss analyst expectationsFirst half 2024 results: EPS: CHF10.66 (up from CHF10.49 in 1H 2023). Revenue: CHF1.09b (down 8.1% from 1H 2023). Net income: CHF249.4m (up 1.6% from 1H 2023). Profit margin: 23% (up from 21% in 1H 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 4.8%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 10% per year.Upcoming Dividend • Aug 06Upcoming dividend of CHF19.25 per shareEligible shareholders must have bought the stock before 13 August 2024. Payment date: 15 August 2024. Payout ratio is a comfortable 65% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Swiss dividend payers (4.4%). Higher than average of industry peers (1.7%).Price Target Changed • Jul 16Price target increased by 8.2% to CHF731Up from CHF675, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of CHF708. Stock is up 2.6% over the past year. The company is forecast to post earnings per share of CHF20.29 for next year compared to CHF19.56 last year.Declared Dividend • Jul 15Dividend of CHF19.25 announcedShareholders will receive a dividend of CHF19.25. Ex-date: 13th August 2024 Payment date: 15th August 2024 Dividend yield will be 2.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 24% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 03EMS-CHEMIE HOLDING AG to Report Fiscal Year 2023 Final Results on Jul 12, 2024EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2023 final results on Jul 12, 2024Reported Earnings • Mar 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: CHF19.71 (down from CHF22.75 in FY 2022). Revenue: CHF2.19b (down 12% from FY 2022). Net income: CHF461.0m (down 13% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 11Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: CHF19.71 (down from CHF22.75 in FY 2022). Revenue: CHF2.19b (down 12% from FY 2022). Net income: CHF461.0m (down 13% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jan 09EMS-CHEMIE HOLDING AG to Report Fiscal Year 2023 Results on Feb 09, 2024EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2023 results on Feb 09, 2024お知らせ • Oct 31EMS-CHEMIE HOLDING AG to Report First Half, 2024 Results on Jul 12, 2024EMS-CHEMIE HOLDING AG announced that they will report first half, 2024 results on Jul 12, 2024お知らせ • Oct 11EMS-CHEMIE HOLDING AG to Report Q3, 2023 Results on Oct 31, 2023EMS-CHEMIE HOLDING AG announced that they will report Q3, 2023 results on Oct 31, 2023Reported Earnings • Sep 01First half 2023 earnings released: EPS: CHF10.48 (vs CHF12.19 in 1H 2022)First half 2023 results: EPS: CHF10.48 (down from CHF12.19 in 1H 2022). Revenue: CHF1.18b (down 7.9% from 1H 2022). Net income: CHF245.0m (down 14% from 1H 2022). Profit margin: 21% (down from 22% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Aug 31EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 10, 2024EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 10, 2024.Upcoming Dividend • Aug 08Upcoming dividend of CHF20.00 per share at 2.8% yieldEligible shareholders must have bought the stock before 15 August 2023. Payment date: 17 August 2023. Payout ratio is a comfortable 69% but the company is paying out more than the cash it is generating. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.1%). Lower than average of industry peers (4.0%).Reported Earnings • Mar 29Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: CHF22.87 (down from CHF23.53 in FY 2021). Revenue: CHF2.44b (up 7.0% from FY 2021). Net income: CHF535.0m (down 2.8% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year.Reported Earnings • Feb 13Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: CHF22.87 (down from CHF23.53 in FY 2021). Revenue: CHF2.44b (up 7.0% from FY 2021). Net income: CHF535.0m (down 2.8% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to stay flat during the next 2 years compared to a 6.2% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Independent Non-Executive Director Christoph Mader was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Oct 31Price target decreased to CHF757Down from CHF849, the current price target is an average from 7 analysts. New target price is 20% above last closing price of CHF630. Stock is down 31% over the past year. The company is forecast to post earnings per share of CHF23.96 for next year compared to CHF23.53 last year.Buying Opportunity • Oct 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be CHF830, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 3.1%. Revenue is forecast to grow by 6.8% in 2 years. Earnings is forecast to grow by 7.6% in the next 2 years.Price Target Changed • Oct 26Price target decreased to CHF826Down from CHF902, the current price target is an average from 7 analysts. New target price is 24% above last closing price of CHF665. Stock is down 29% over the past year. The company is forecast to post earnings per share of CHF24.02 for next year compared to CHF23.53 last year.お知らせ • Oct 18EMS-CHEMIE HOLDING AG to Report Q3, 2022 Results on Oct 25, 2022EMS-CHEMIE HOLDING AG announced that they will report Q3, 2022 results on Oct 25, 2022Reported Earnings • Sep 01First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst half 2022 results: EPS: CHF12.20 (up from CHF11.89 in 1H 2021). Revenue: CHF1.28b (up 10% from 1H 2021). Net income: CHF285.0m (up 2.5% from 1H 2021). Profit margin: 22% (down from 24% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 6.2%, compared to a 13% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 6% per year.お知らせ • Aug 26+ 1 more updateEMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 12, 2023EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 12, 2023.Upcoming Dividend • Aug 09Upcoming dividend of CHF21.00 per shareEligible shareholders must have bought the stock before 16 August 2022. Payment date: 18 August 2022. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.0%). Higher than average of industry peers (1.8%).お知らせ • Jul 16EMS-CHEMIE HOLDING AG Proposes DividendEMS-CHEMIE HOLDING AG proposed a dividend payment of total CHF 21.00 (CHF 17.00) per share at the to be held ordinary annual general meeting held on August 13, 2022.Buying Opportunity • Jun 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 10.0%. The fair value is estimated to be CHF947, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.0% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Christoph Maeder was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 20EMS-CHEMIE HOLDING AG to Report Q1, 2022 Results on Apr 27, 2022EMS-CHEMIE HOLDING AG announced that they will report Q1, 2022 results on Apr 27, 2022Reported Earnings • Mar 28Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: CHF23.53 (up from CHF18.57 in FY 2020). Revenue: CHF2.28b (up 25% from FY 2020). Net income: CHF550.3m (up 27% from FY 2020). Profit margin: 24% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Reported Earnings • Feb 13Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: CHF23.64 (up from CHF18.57 in FY 2020). Revenue: CHF2.25b (up 23% from FY 2020). Net income: CHF553.0m (up 27% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 10%, compared to a 9.4% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.Buying Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.1%. The fair value is estimated to be CHF1,149, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.2% per annum over the last 3 years. Earnings per share has declined by 4.1% per annum over the last 3 years.Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Christoph Maeder was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 01First half 2021 earnings released: EPS CHF11.89 (vs CHF8.17 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF1.17b (up 38% from 1H 2020). Net income: CHF278.0m (up 46% from 1H 2020). Profit margin: 24% (up from 23% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Upcoming Dividend • Aug 03Upcoming dividend of CHF17.00 per shareEligible shareholders must have bought the stock before 10 August 2021. Payment date: 12 August 2021. Trailing yield: 1.7%. Lower than top quartile of Swiss dividend payers (3.5%). Higher than average of industry peers (1.2%).Price Target Changed • Jul 26Price target increased to CHF936Up from CHF844, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF966. Stock is up 21% over the past year.Price Target Changed • Apr 24Price target increased to CHF801Up from CHF712, the current price target is an average from 5 analysts. New target price is 9.3% below last closing price of CHF883. Stock is up 39% over the past year.Reported Earnings • Mar 27Full year 2020 earnings released: EPS CHF18.57 (vs CHF22.54 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF1.83b (down 17% from FY 2019). Net income: CHF434.3m (down 18% from FY 2019). Profit margin: 24% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.業績と収益の成長予測SWX:EMSN - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,164559509580612/31/20272,069533490565712/31/20261,976504492548712/31/20251,969467506534N/A9/30/20251,996464476507N/A6/30/20252,024462445479N/A3/31/20252,057461446480N/A12/31/20242,091461448480N/A9/30/20242,104461473505N/A6/30/20242,117462499529N/A3/31/20242,165460513553N/A12/31/20232,213458527576N/A9/30/20232,294475456523N/A6/30/20232,374493385469N/A3/31/20232,425512328418N/A12/31/20222,475532272366N/A9/30/20222,438545297385N/A6/30/20222,401557322403N/A3/31/20222,342554380461N/A12/31/20212,283550438518N/A9/30/20212,218536443512N/A6/30/20212,154521447507N/A3/31/20211,994478435489N/A12/31/20201,833434423472N/A9/30/20201,867444443497N/A6/30/20201,900453462522N/A3/31/20202,055490476537N/A12/31/20192,209527489552N/A9/30/20192,257527N/A541N/A6/30/20192,305527N/A529N/A3/31/20192,327523N/A514N/A12/31/20182,350520N/A499N/A9/30/20182,330517N/A509N/A6/30/20182,310515N/A520N/A3/31/20182,243498N/A481N/A12/31/20172,177482N/A443N/A9/30/20172,126471N/A446N/A6/30/20172,076461N/A449N/A3/31/20172,044455N/A468N/A12/31/20162,012449N/A486N/A9/30/20161,987428N/A467N/A6/30/20161,962407N/A449N/A3/31/20161,947392N/A429N/A12/31/20151,932376N/A410N/A9/30/20151,944360N/A427N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: EMSNの予測収益成長率 (年間6% ) は 貯蓄率 ( 0.6% ) を上回っています。収益対市場: EMSNの収益 ( 6% ) Swiss市場 ( 12.1% ) よりも低い成長が予測されています。高成長収益: EMSNの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: EMSNの収益 ( 3.2% ) Swiss市場 ( 5.3% ) よりも低い成長が予測されています。高い収益成長: EMSNの収益 ( 3.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EMSNの 自己資本利益率 は、3年後には高くなると予測されています ( 27.6 %)成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/05 18:29終値2026/08/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EMS-CHEMIE HOLDING AG 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Konstantin WiechertBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchAdrien TamagnoBerenberg11 その他のアナリストを表示
Price Target Changed • Jul 14Price target increased by 7.1% to CHF708Up from CHF661, the current price target is an average from 7 analysts. New target price is 7.1% below last closing price of CHF763. Stock is up 21% over the past year. The company is forecast to post earnings per share of CHF21.45 for next year compared to CHF19.95 last year.
Price Target Changed • Jul 16Price target increased by 8.2% to CHF731Up from CHF675, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of CHF708. Stock is up 2.6% over the past year. The company is forecast to post earnings per share of CHF20.29 for next year compared to CHF19.56 last year.
Price Target Changed • Oct 31Price target decreased to CHF757Down from CHF849, the current price target is an average from 7 analysts. New target price is 20% above last closing price of CHF630. Stock is down 31% over the past year. The company is forecast to post earnings per share of CHF23.96 for next year compared to CHF23.53 last year.
Price Target Changed • Oct 26Price target decreased to CHF826Down from CHF902, the current price target is an average from 7 analysts. New target price is 24% above last closing price of CHF665. Stock is down 29% over the past year. The company is forecast to post earnings per share of CHF24.02 for next year compared to CHF23.53 last year.
Price Target Changed • Jul 26Price target increased to CHF936Up from CHF844, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF966. Stock is up 21% over the past year.
Price Target Changed • Apr 24Price target increased to CHF801Up from CHF712, the current price target is an average from 5 analysts. New target price is 9.3% below last closing price of CHF883. Stock is up 39% over the past year.
分析記事 • Aug 04Is EMS-CHEMIE HOLDING AG (VTX:EMSN) Potentially Undervalued?Let's talk about the popular EMS-CHEMIE HOLDING AG ( VTX:EMSN ). The company's shares received a lot of attention from...
Buy Or Sell Opportunity • Jul 29Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to CHF809. The fair value is estimated to be CHF667, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 3.2% per annum. Earnings are also forecast to grow by 6.0% per annum over the same time period.
Price Target Changed • Jul 14Price target increased by 7.1% to CHF708Up from CHF661, the current price target is an average from 7 analysts. New target price is 7.1% below last closing price of CHF763. Stock is up 21% over the past year. The company is forecast to post earnings per share of CHF21.45 for next year compared to CHF19.95 last year.
お知らせ • Jul 13EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time.
Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.
お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026
分析記事 • Jan 14Estimating The Fair Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)Key Insights Using the 2 Stage Free Cash Flow to Equity, EMS-CHEMIE HOLDING fair value estimate is CHF601 EMS-CHEMIE...
お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026
分析記事 • Dec 27EMS-CHEMIE HOLDING AG's (VTX:EMSN) Share Price Could Signal Some RiskEMS-CHEMIE HOLDING AG's ( VTX:EMSN ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right...
分析記事 • Nov 12Investors Met With Slowing Returns on Capital At EMS-CHEMIE HOLDING (VTX:EMSN)If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
分析記事 • Oct 27Is EMS-CHEMIE HOLDING (VTX:EMSN) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Sep 01First half 2025 earnings released: EPS: CHF10.71 (vs CHF10.66 in 1H 2024)First half 2025 results: EPS: CHF10.71 (up from CHF10.66 in 1H 2024). Revenue: CHF1.02b (down 6.2% from 1H 2024). Net income: CHF250.4m (flat on 1H 2024). Profit margin: 25% (up from 23% in 1H 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 3% per year.
Upcoming Dividend • Aug 05Upcoming dividend of CHF17.25 per shareEligible shareholders must have bought the stock before 12 August 2025. Payment date: 14 August 2025. Payout ratio is a comfortable 71% and the cash payout ratio is 90%. Trailing yield: 2.7%. Lower than top quartile of Swiss dividend payers (3.9%). In line with average of industry peers (2.8%).
お知らせ • Jul 15EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time.
Declared Dividend • Jul 14Dividend increased to CHF17.25Dividend of CHF17.25 is 7.8% higher than last year. Ex-date: 12th August 2025 Payment date: 14th August 2025 Dividend yield will be 2.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (71% earnings payout ratio) but not adequately covered by cash flows (90.1% cash payout ratio). The dividend has increased by an average of 3.7% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jul 13EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.
お知らせ • Apr 01EMS-CHEMIE HOLDING AG to Report Fiscal Year 2024 Final Results on Jul 11, 2025EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2024 final results on Jul 11, 2025
Reported Earnings • Mar 31Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: CHF19.70 (up from CHF19.56 in FY 2023). Revenue: CHF2.09b (down 5.5% from FY 2023). Net income: CHF460.8m (flat on FY 2023). Profit margin: 22% (up from 21% in FY 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 12% per year.
Buy Or Sell Opportunity • Mar 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 7.2% to CHF677. The fair value is estimated to be CHF561, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 4.9% over the last 3 years. Earnings per share has declined by 7.8%. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings are also forecast to grow by 5.0% per annum over the same time period.
お知らせ • Nov 27EMS-CHEMIE HOLDING AG to Report Fiscal Year 2024 Results on Feb 07, 2025EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2024 results on Feb 07, 2025
お知らせ • Oct 23EMS-CHEMIE HOLDING AG to Report First Half, 2025 Results on Jul 11, 2025EMS-CHEMIE HOLDING AG announced that they will report first half, 2025 results on Jul 11, 2025
Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 02First half 2024 earnings: EPS and revenues miss analyst expectationsFirst half 2024 results: EPS: CHF10.66 (up from CHF10.49 in 1H 2023). Revenue: CHF1.09b (down 8.1% from 1H 2023). Net income: CHF249.4m (up 1.6% from 1H 2023). Profit margin: 23% (up from 21% in 1H 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 4.8%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 10% per year.
Upcoming Dividend • Aug 06Upcoming dividend of CHF19.25 per shareEligible shareholders must have bought the stock before 13 August 2024. Payment date: 15 August 2024. Payout ratio is a comfortable 65% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Swiss dividend payers (4.4%). Higher than average of industry peers (1.7%).
Price Target Changed • Jul 16Price target increased by 8.2% to CHF731Up from CHF675, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of CHF708. Stock is up 2.6% over the past year. The company is forecast to post earnings per share of CHF20.29 for next year compared to CHF19.56 last year.
Declared Dividend • Jul 15Dividend of CHF19.25 announcedShareholders will receive a dividend of CHF19.25. Ex-date: 13th August 2024 Payment date: 15th August 2024 Dividend yield will be 2.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 24% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 03EMS-CHEMIE HOLDING AG to Report Fiscal Year 2023 Final Results on Jul 12, 2024EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2023 final results on Jul 12, 2024
Reported Earnings • Mar 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: CHF19.71 (down from CHF22.75 in FY 2022). Revenue: CHF2.19b (down 12% from FY 2022). Net income: CHF461.0m (down 13% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 11Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: CHF19.71 (down from CHF22.75 in FY 2022). Revenue: CHF2.19b (down 12% from FY 2022). Net income: CHF461.0m (down 13% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jan 09EMS-CHEMIE HOLDING AG to Report Fiscal Year 2023 Results on Feb 09, 2024EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2023 results on Feb 09, 2024
お知らせ • Oct 31EMS-CHEMIE HOLDING AG to Report First Half, 2024 Results on Jul 12, 2024EMS-CHEMIE HOLDING AG announced that they will report first half, 2024 results on Jul 12, 2024
お知らせ • Oct 11EMS-CHEMIE HOLDING AG to Report Q3, 2023 Results on Oct 31, 2023EMS-CHEMIE HOLDING AG announced that they will report Q3, 2023 results on Oct 31, 2023
Reported Earnings • Sep 01First half 2023 earnings released: EPS: CHF10.48 (vs CHF12.19 in 1H 2022)First half 2023 results: EPS: CHF10.48 (down from CHF12.19 in 1H 2022). Revenue: CHF1.18b (down 7.9% from 1H 2022). Net income: CHF245.0m (down 14% from 1H 2022). Profit margin: 21% (down from 22% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Aug 31EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 10, 2024EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 10, 2024.
Upcoming Dividend • Aug 08Upcoming dividend of CHF20.00 per share at 2.8% yieldEligible shareholders must have bought the stock before 15 August 2023. Payment date: 17 August 2023. Payout ratio is a comfortable 69% but the company is paying out more than the cash it is generating. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.1%). Lower than average of industry peers (4.0%).
Reported Earnings • Mar 29Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: CHF22.87 (down from CHF23.53 in FY 2021). Revenue: CHF2.44b (up 7.0% from FY 2021). Net income: CHF535.0m (down 2.8% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year.
Reported Earnings • Feb 13Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: CHF22.87 (down from CHF23.53 in FY 2021). Revenue: CHF2.44b (up 7.0% from FY 2021). Net income: CHF535.0m (down 2.8% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to stay flat during the next 2 years compared to a 6.2% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Independent Non-Executive Director Christoph Mader was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Oct 31Price target decreased to CHF757Down from CHF849, the current price target is an average from 7 analysts. New target price is 20% above last closing price of CHF630. Stock is down 31% over the past year. The company is forecast to post earnings per share of CHF23.96 for next year compared to CHF23.53 last year.
Buying Opportunity • Oct 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be CHF830, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 3.1%. Revenue is forecast to grow by 6.8% in 2 years. Earnings is forecast to grow by 7.6% in the next 2 years.
Price Target Changed • Oct 26Price target decreased to CHF826Down from CHF902, the current price target is an average from 7 analysts. New target price is 24% above last closing price of CHF665. Stock is down 29% over the past year. The company is forecast to post earnings per share of CHF24.02 for next year compared to CHF23.53 last year.
お知らせ • Oct 18EMS-CHEMIE HOLDING AG to Report Q3, 2022 Results on Oct 25, 2022EMS-CHEMIE HOLDING AG announced that they will report Q3, 2022 results on Oct 25, 2022
Reported Earnings • Sep 01First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst half 2022 results: EPS: CHF12.20 (up from CHF11.89 in 1H 2021). Revenue: CHF1.28b (up 10% from 1H 2021). Net income: CHF285.0m (up 2.5% from 1H 2021). Profit margin: 22% (down from 24% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 6.2%, compared to a 13% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 6% per year.
お知らせ • Aug 26+ 1 more updateEMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 12, 2023EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 12, 2023.
Upcoming Dividend • Aug 09Upcoming dividend of CHF21.00 per shareEligible shareholders must have bought the stock before 16 August 2022. Payment date: 18 August 2022. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.0%). Higher than average of industry peers (1.8%).
お知らせ • Jul 16EMS-CHEMIE HOLDING AG Proposes DividendEMS-CHEMIE HOLDING AG proposed a dividend payment of total CHF 21.00 (CHF 17.00) per share at the to be held ordinary annual general meeting held on August 13, 2022.
Buying Opportunity • Jun 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 10.0%. The fair value is estimated to be CHF947, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.0% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Christoph Maeder was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 20EMS-CHEMIE HOLDING AG to Report Q1, 2022 Results on Apr 27, 2022EMS-CHEMIE HOLDING AG announced that they will report Q1, 2022 results on Apr 27, 2022
Reported Earnings • Mar 28Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: CHF23.53 (up from CHF18.57 in FY 2020). Revenue: CHF2.28b (up 25% from FY 2020). Net income: CHF550.3m (up 27% from FY 2020). Profit margin: 24% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 13Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: CHF23.64 (up from CHF18.57 in FY 2020). Revenue: CHF2.25b (up 23% from FY 2020). Net income: CHF553.0m (up 27% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 10%, compared to a 9.4% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
Buying Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.1%. The fair value is estimated to be CHF1,149, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.2% per annum over the last 3 years. Earnings per share has declined by 4.1% per annum over the last 3 years.
Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Christoph Maeder was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 01First half 2021 earnings released: EPS CHF11.89 (vs CHF8.17 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF1.17b (up 38% from 1H 2020). Net income: CHF278.0m (up 46% from 1H 2020). Profit margin: 24% (up from 23% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Upcoming Dividend • Aug 03Upcoming dividend of CHF17.00 per shareEligible shareholders must have bought the stock before 10 August 2021. Payment date: 12 August 2021. Trailing yield: 1.7%. Lower than top quartile of Swiss dividend payers (3.5%). Higher than average of industry peers (1.2%).
Price Target Changed • Jul 26Price target increased to CHF936Up from CHF844, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF966. Stock is up 21% over the past year.
Price Target Changed • Apr 24Price target increased to CHF801Up from CHF712, the current price target is an average from 5 analysts. New target price is 9.3% below last closing price of CHF883. Stock is up 39% over the past year.
Reported Earnings • Mar 27Full year 2020 earnings released: EPS CHF18.57 (vs CHF22.54 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF1.83b (down 17% from FY 2019). Net income: CHF434.3m (down 18% from FY 2019). Profit margin: 24% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.